Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 23;60(10):6407-10.
doi: 10.1128/AAC.01282-16. Print 2016 Oct.

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms

Gabriel Torrens  1 , Gabriel Cabot  2 , Alain A Ocampo-Sosa  3 , M Carmen Conejo  4 , Laura Zamorano  1 , Ferrán Navarro  5 , Álvaro Pascual  4 , Luis Martínez-Martínez  6 , Antonio Oliver  1
Affiliations

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms

Gabriel Torrens et al. Antimicrob Agents Chemother. .

Abstract

The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(A) Ceftazidime (CAZ) and ceftazidime-avibactam (CAZ-AVI) MIC distributions for a collection of 190 P. aeruginosa bloodstream isolates recovered from a 10-hospital multicenter study performed in Spain. (B) CAZ and CAZ-AVI MIC distribution for the 46 isolates from the collection showing AmpC hyperproduction. (C) CAZ and CAZ-AVI MIC distribution for the 63 isolates from the collection showing an MDR profile.
See this image and copyright information in PMC

References

    1. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582–610. doi: 10.1128/CMR.00040-09. - DOI - PMC - PubMed
    1. Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A. 2011. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 66:2022–2027. doi: 10.1093/jac/dkr232. - DOI - PubMed
    1. Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A. 2012. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 56:4771–4778. doi: 10.1128/AAC.00680-12. - DOI - PMC - PubMed
    1. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. 2016. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomized, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661–673. doi: 10.1016/S1473-3099(16)30004-4. - DOI - PubMed
    1. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2011. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906–1911. doi: 10.1128/AAC.01645-10. - DOI - PMC - PubMed

MeSH terms